Pharmacokinetics of AXA1665, a Novel Composition of Amino Acids, in Comparison With Protein Supplement: A Single‐Dose, Open‐Label, Randomized Study in Healthy Subjects

Abstract

We evaluated the safety and tolerability of AXA1665, a novel investigational fixed‐ratio amino acid (AA) composition, the pharmacokinetics (PK) of the constituent AAs within AXA1665, and their relative bioavailability versus standard protein supplement. This study was conducted in 2 phases; in the initial phase, healthy subjects (N = 16) were randomly assigned to 4 treatment sequences (AXA1665 4.9, 9.8, and 19.6 g or 35 g protein supplement) in an open‐label, single‐dose, 4‐way crossover study, while in the extension phase, they received single AXA1665 doses of 29.4 and 39.2 g in a sequential crossover manner. The net area under the plasma concentration–time curve (AUC) and observed time to reach maximum plasma concentration were estimated. A dose‐dependent increase in plasma AUC from time 0 to the last measurable concentration (AUClast) and maximum plasma concentration (Cmax) was observed for all AXA1665‐dosed AAs (4.9–39.2 g) except aspartic acid. AXA1665 19.6 g resulted in 1.5‐ to 9.5‐fold higher systemic exposure to all AXA1665‐dosed AAs except for aspartic acid and lysine and lower exposure to all nondosed AAs except for glutamine and alanine versus protein supplement. AXA1665 doses, up to 39.2 g, can deliver AXA1665‐dosed AAs in the systemic circulation in the linear AUC range.